Navigation Links
ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion)

the scientific literature or conclusions regarding safety or effectiveness made by the FDA in the approval of other drugs. This regulatory pathway potentially makes it easier for drug manufacturers to obtain rapid approval of new forms of drugs based on the FDA's approval of the original drug. Some examples of products that may be allowed to follow a 505(b)(2) path to approval are drugs that have a new dosage form, strength, route of administration, formulation or indication. Upon approval, a drug may be marketed only for the FDA-approved indications in the approved dosage forms. Further clinical trials are necessary to gain approval for the use of the product for any additional indications or dosage forms.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that preclinical and clinical results are not indicative of the success of subsequent clinical trials and that products will not perform as preclinical and clinical data suggests or
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ... research report to its store . ... from aging of population, consumption upgrade and policy ... industry has seen rapid development over the years, ... yuan in 2006 to 9.85 billion yuan in ...
(Date:1/15/2014)... AARP Foundation today announced it has established a ... the severe cold weather that has gripped much of ... helping those in need; so to support these emergency ... contributions up to $250,000, which could mean up to ... through AARP Foundation. (Logo: http://photos.prnewswire.com/prnh/20070209/NYF043LOGO ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Office of Fair Trading (OFT) approval condition to the announced ... Incorporated (NASDAQ: VPHM).   As a result of ... approval, and Shire expects to complete the tender offer on ... to the satisfaction of all of the remaining conditions to ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Nov. 14 The following is,the prepared testimony of ... and Drug Administration (FDA) regarding behind the counter,availability of ... of the National Community,Pharmacists Association (NCPA) and a pharmacist ... thank the FDA for holding this public meeting to,explore ...
... CHAPEL HILL, N.C., Nov. 14 Research that ... new product,launches to manufacturing and online financial services ... an online research repository managed by,research and consulting ... key findings and key metrics in these studies, ...
... The finding might help lead to new treatments, scientists say ... they,ve have uncovered a biological "switch" for key genes in ... are silenced by distinct changes in the density of structures ... the first time exactly how genes get shut down in ...
... has indicated that FlexNow(R) Joint Formula shows significant, ... pain., EGG HARBOR TWP., N.J., Nov. 14 ... FlexNow(R) Joint Formula, has announced the,findings from the ... June,at the Australian Centre for Complementary Medicine Education ...
... from Peripheral Arterial Disease is Caused,by Smoking, ... well,aware of the risk of cancer from smoking, ... body,s vascular system. Smoking damages the,blood vessels and ... including,peripheral arterial disease (PAD), stroke, heart attack, abdominal ...
... 14 Following is a statement,by Linda A. ... (CHPA), regarding today,s FDA public meeting seeking comments,on ... behalf of our member companies, CHPA was pleased ... discussion of expanded consumer,access to medicines. As the ...
Cached Medicine News:Health News:NCPA President Steve Giroux's Testimony at FDA Behind the Counter Hearing 2Health News:NCPA President Steve Giroux's Testimony at FDA Behind the Counter Hearing 3Health News:NCPA President Steve Giroux's Testimony at FDA Behind the Counter Hearing 4Health News:NCPA President Steve Giroux's Testimony at FDA Behind the Counter Hearing 5Health News:Best Practice Database Adds New Research on New Product Launches, Online Financial Services and Manufacturing Operations 2Health News:Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clinical Study 2Health News:A New Reason to Quit for the Great American Smokeout 2Health News:Statement From the Consumer Healthcare Products Association on Proposed New 'Third Class' of Medicines 2
... onboard rail clamps mount ... tables and stretchers. The ... need for lifting. Easy ... stable surface combined with ...
The DHS Basic Set is available with either self-tapping or non-self-tapping screws. Either instrument set provides complete instrumentation in one graphic case for use with the Universal Implant Set,...
... is a versatile, fully powered orthopaedic and ... traction facilities, a powered centre break and ... versatile too. ,<br.,In fact the RX600 is ... it is for traction procedures. The RX600 ...
... orthopedic trauma procedures. Part of the ... trauma table top provides a complete, ... positioning and provides for skin or ... hip pinnings; femur, supine or lateral ...
Medicine Products: